Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Halozyme Therapeutics Inc

Current price
53.18 USD +0.36 USD (+0.68%)
Last closed 52.82 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 562 247 680 USD
Yield for 12 month +39.14 %
21.11.2021 - 28.11.2021

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Address: 12390 El Camino Real, San Diego, CA, United States, 92130

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

57.89 USD

P/E ratio


Dividend Yield

Current Year

+829 253 000 USD

Last Year

+660 116 000 USD

Current Quarter

+195 879 000 USD

Last Quarter

+230 039 000 USD

Current Year

+636 892 000 USD

Last Year

+520 812 000 USD

Current Quarter

+149 787 000 USD

Last Quarter

+177 741 000 USD

Key Figures HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 458 419 008 USD
Operating Margin TTM 48.78 %
PE Ratio 21.3942
Return On Assets TTM 13.48 %
PEG Ratio -2.5
Return On Equity TTM 261.68 %
Wall Street Target Price 57.89 USD
Revenue TTM 862 988 992 USD
Book Value 1.4 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 20.8 %
Dividend Yield
Gross Profit TTM 454 205 000 USD
Earnings per share 2.41 USD
Diluted Eps TTM 2.41 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 106.9 %
Profit Margin 36.94 %

Dividend Analytics HALO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 171:40
Payout Ratio
Last Split Date 10.12.2003
Dividend Date

Stock Valuation HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 21.3942
Forward PE 12.6263
Enterprise Value Revenue 7.3199
Price Sales TTM 5.9156
Enterprise Value EBITDA 13.431
Price Book MRQ 58.5485

Financials HALO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators HALO

For 52 weeks

32.83 USD 53.22 USD
50 Day MA 46.01 USD
Shares Short Prior Month 8 562 180
200 Day MA 39.91 USD
Short Ratio 7.07
Shares Short 9 308 538
Short Percent 9.89 %

Dynamics of changes in the value of assets



25.82 EUR Wizz Air Holdings PLC -0.02 (-0.08%)
Detailed analytics


36.80 EUR Holmen AB (publ) +0.11 (+0.27%)
Detailed analytics


12.20 EUR KT Corporation +0.11 (+0.83%)
Detailed analytics


12.16 HKD ESR Cayman Ltd +0.02 (+1.33%)
Detailed analytics


64.65 USD Union Electric Company 0 (0%)
Detailed analytics